Lexaria Bioscience (LEXX) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Lexaria Bioscience has appointed esteemed Harvard Medical School Professor Dr. Michael Gibson as Chief Medical Advisor to enhance its innovative drug delivery platform, DehydraTECH, particularly for hypertension and GLP-1 applications. Dr. Gibson brings significant expertise in cardiovascular research and clinical trials, promising to advance Lexaria’s drug development and optimization efforts. His extensive background and leadership in influential healthcare research are expected to drive Lexaria’s growth and improve pharmacokinetic drug performance.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
